Pancreatic Cancer Research

Clinical trialPhase 1Withdrawn

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pilot Study of 89Zr Panitumumab in Pancreas Cancer

Outcome
Stopped earlyBusiness Decision (Business decision)
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
26 March 2021
Planned end
March 2024
Enrollment
0 participants
Sites
1
Primary outcomes
Incidence of treatment emergent adverse events assessed by CTCAE v5
Sponsor type
Academic / other
Results posted
No
Last update
21 June 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.